Compare STRT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | GLSI |
|---|---|---|
| Founded | 1908 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.7M | 372.0M |
| IPO Year | 1996 | 2020 |
| Metric | STRT | GLSI |
|---|---|---|
| Price | $76.63 | $26.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $93.00 | $50.00 |
| AVG Volume (30 Days) | 84.2K | ★ 112.6K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.53 | N/A |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $439,195,000.00 | N/A |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $23.39 | ★ N/A |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $31.71 | $7.78 |
| 52 Week High | $92.50 | $34.10 |
| Indicator | STRT | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 52.63 |
| Support Level | $72.27 | $21.20 |
| Resistance Level | $84.29 | $30.02 |
| Average True Range (ATR) | 3.68 | 1.85 |
| MACD | 0.32 | 0.37 |
| Stochastic Oscillator | 21.42 | 70.21 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.